Evidence map›Paper›PMID 40439668›Full record

ArticleBriefings in bioinformatics2025

PPIxGPN: plasma proteomic profiling of neurodegenerative biomarkers with protein-protein interaction-based eXplainable graph propagational network.

Sunghong Park, Dong-Gi Lee, Juhyeon Kim, Seung Ho Kim, Hyeon Jin Hwang, Hyunjung Shin, Hyun Goo Woo

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sunghong ParkDepartment of Physiology, Ajou University School of Medicine, Worldcup-ro 164, Yeongtong-gu, Suwon, 16499, Republic of Korea.ORCID 0000-0002-5158-4670
Dong-Gi LeeDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Juhyeon KimDepartment of Industrial Engineering, Ajou University, Worldcup-ro 206, Yeongtong-gu, Suwon, 16499, Republic of Korea.
Seung Ho KimDepartment of Physiology, Ajou University School of Medicine, Worldcup-ro 164, Yeongtong-gu, Suwon, 16499, Republic of Korea.
Hyeon Jin HwangDepartment of Physiology, Ajou University School of Medicine, Worldcup-ro 164, Yeongtong-gu, Suwon, 16499, Republic of Korea.
Hyunjung ShinDepartment of Industrial Engineering, Ajou University, Worldcup-ro 206, Yeongtong-gu, Suwon, 16499, Republic of Korea.ORCID 0000-0001-8347-8277
Hyun Goo WooDepartment of Physiology, Ajou University School of Medicine, Worldcup-ro 164, Yeongtong-gu, Suwon, 16499, Republic of Korea.ORCID 0000-0002-0916-893X

Funding

Ajou University Research FundBasic Science Research ProgramInstitute of Information & Communications Technology Planning & Evaluation grant RS-2023-00255968Korea Health Technology R&D Project through Korea Health Industry Development InstituteMinistry of Education, Republic of Korea 2022R1A6A3A01086784Ministry of Health and Welfare, Republic of Korea RS-2021-KH113821Ministry of Science and ICT, Republic of Korea 2019R1A5A2026045Ministry of Science and ICT, Republic of Korea 2021R1A2C2003474Ministry of Science and ICT, Republic of Korea RS-2022-001653National Research Foundation of Korea
6 · The paper itself

Abstract

Neurodegenerative diseases involve progressive neuronal dysfunction, requiring the identification of specific pathological features for accurate diagnosis. While cerebrospinal fluid analysis and neuroimaging are commonly used, their invasive nature and high costs limit clinical applicability. Recently advances in plasma proteomics offer a less invasive and cost-effective alternative, further enhanced by machine learning (ML). However, most ML-based studies overlook synergetic effects from protein-protein interactions (PPIs), which play a key role in disease mechanisms. Although graph convolutional network and its extensions can utilize PPIs, they rely on locality-based feature aggregation, overlooking essential components and emphasizing noisy interactions. Moreover, expanding those methods to cover broader PPIs results in complex model architectures that reduce explainability, which is crucial in medical ML models for clinical decision-making. To address these challenges, we propose Protein-Protein Interaction-based eXplainable Graph Propagational Network (PPIxGPN), a novel ML model designed for plasma proteomic profiling of neurodegenerative biomarkers. PPIxGPN captures synergetic effects between proteins by integrating PPIs with independent effects of proteins, leveraging globality-based feature aggregation to represent comprehensive PPI properties. This process is implemented using a single graph propagational layer, enabling PPIxGPN to be configured by shallow architecture, thereby PPIxGPN ensures high model explainability, enhancing clinical applicability by providing interpretable outputs. Experimental validation on the UK Biobank dataset demonstrated the superior performance of PPIxGPN in neurodegenerative risk prediction, outperforming comparison methods. Furthermore, the explainability of PPIxGPN facilitated detailed analyses of the discriminative significance of synergistic effects, the predictive importance of proteins, and the longitudinal changes in biomarker profiles, highlighting its clinical relevance.

Indexed as

BiomarkersBlood ProteinsNeurodegenerative DiseasesProtein Interaction MapsProteomicsHumansMachine LearningProtein Interaction MappingBiomarkersBlood Proteinsblood-based biomarkersexplainable machine learninggraph neural networkneurodegenerative diseasesprotein–protein interaction

Identifiers

PMID40439668
PMCPMC12121361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.